Compare
Bioforce Nanosciences Holdings, Inc. vs Astrotech Corp vs Precipio, Inc. vs Bionano Genomics, Inc.
| Latest fiscal year | Bioforce Nanosciences Holdings, Inc. BFNH | Astrotech Corp ASTC | Precipio, Inc. PRPO | Bionano Genomics, Inc. BNGO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-06-30 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $913.0K | $24.05M | $28.51M |
| Revenue growth (YoY) | n/a | -13.0% | +29.8% | -7.4% |
| Gross margin | n/a | 23.8% | 44.5% | 46.3% (computed) |
| Operating margin | n/a | n/m | -5.0% | -116.9% |
| Net margin | n/a | n/m | -1.5% | -92.6% |
| Net income | -$1.29M | -$14.43M | -$363.0K | -$26.39M |
| EPS (Diluted) | -$0.04 | n/a | -$0.23 | -$4.85 |
| Operating cash flow | -$65.2K | -$13.45M | $685.0K | -$16.34M |
| Free cash flow | n/a | -$14.33M | $359.0K | n/a |
| Cash & equivalents | $786 | $8.39M | $2.65M | $2.99M |
| Total assets | $786 | $20.51M | $21.32M | $73.58M |
| Total liabilities | $619.3K | $4.33M | $6.76M | $29.16M |
| Shareholders' equity | -$618.5K | $16.17M | $14.56M | $44.42M |
| Return on year-end equity | n/a | -89.2% | -2.5% | -59.4% |
| Shares outstanding | 33.52M | 2.00M | 1.78M | 10.74M |
Revenue, most recent five fiscal years
| Fiscal year | Bioforce Nanosciences Holdings, Inc. | Astrotech Corp | Precipio, Inc. | Bionano Genomics, Inc. |
|---|---|---|---|---|
| Latest | $17.8K Ended 2019-12-31 | $913.0K Ended 2026-06-30 | $24.05M Ended 2025-12-31 | $28.51M Ended 2025-12-31 |
| 1 year earlier | $16.3K Ended 2018-12-31 | $1.05M Ended 2025-06-30 | $18.53M Ended 2024-12-31 | $30.78M Ended 2024-12-31 |
| 2 years earlier | $4.5K Ended 2017-12-31 | $1.66M Ended 2024-06-30 | $15.20M Ended 2023-12-31 | $36.12M Ended 2023-12-31 |
| 3 years earlier | n/a | $750.0K Ended 2023-06-30 | $9.41M Ended 2022-12-31 | $27.80M Ended 2022-12-31 |
| 4 years earlier | n/a | $869.0K Ended 2022-06-30 | $8.85M Ended 2021-12-31 | $17.98M Ended 2021-12-31 |